GlobalData on MSN20h
MSD secures worldwide license for LaNova’s LM-299
MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...
Medscape3d
Researchers Identify Why Some Don’t Respond to Anti-VEGF Drugs for AMD
in patients who failed therapy with drugs targeting vascular endothelial growth factor (VEGF). Sodhi and his ...
The Manhattan Mercury11d
Why Treatments Can Fail Folks With 'Wet' Macular Degeneration -- and What Might Really Work
To combat this, doctors prescribe medications that slow the growth of new blood vessels, called anti-VEGF (vascular ...
GlobalData on MSN1d
BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
New Atlas6d
RNA therapy an effective alternative to lifelong, painful eye injections
An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...
Merck in Cancer Licensing Pact With LaNova Medicines
Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.
Finance News Network1d
Eye on the prize: $15.9m boost for Opthea's vision impairment therapy
Nov 2024 - Opthea (ASX:OPT) has announced a boost to its cash reserves, receiving a $15.9m research and development tax ...
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...